drugset / Trial / NCT05954442
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the efficacy of investigator's choice of chemotherapy, either alone or in combination with everolimus, in treating patients with locally recurrent inoperable or metastatic triple-negative breast cancer, luminal androgen receptor (LAR) subtype with PI3K/AKT/mTOR (PAM) pathway mutation, as the first-line treatment.
Timeline
- Start
- 2023-09-13
- Primary completion
- 2025-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Epothilone D | Small molecule | — | — |
| Subject | Eribulin | Small molecule | — | — |
| Subject | Everolimus | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Vinorelbine | Small molecule | — | — |